overview of unicef procurement and … of unicef procurement and current challenges jon blasco, ......
Post on 01-Apr-2018
235 Views
Preview:
TRANSCRIPT
HIV/AIDS & MALARIA
MEDICINES
OVERVIEW OF UNICEF PROCUREMENT
AND CURRENT CHALLENGES
Jon Blasco, Contracts Specialist
Pharmaceutical Manufacturers Meeting
UNICEF SD, 27 Sept 2010
HIV/AIDS & MALARIA UNICEF PROCUREMENT 2008-2010(YTD)
0
20
40
60
80
100
120
2008 2009 2010
USD
Mill
ion
s
Other antimalarials
ARVs
ACTs
ANTIRETROVIRAL MEDICINESTOP 10 FORMULATIONS 2009
0 5 10 15 20 25
3TC150mg tabs
LPV+RTV 200+50mg heat/st tabs
d4T+3TC 30+150mg tabs
NVP 200mg tabs
TDF300mg tabs
AZT 300mg tabs
AZT + 3TC 300+150mg tabs
EFV 600mg tabs
d4T+3TC+NVP 30+150+200mg tabs
ZDV+3TC+NVP 300+150+200mg tabs
USD Millions
0 10 20 30
TDF 300mg tabs
NVP 200mg tabs
d4T+3TC 30+150mg tabs
ABC 300mg tabs
LPV/r 200mg/50mg heat/st tabs
AZT 300mg tabs
ZDV + 3TC 300+150mg tabs
EFV 600mg tabs
ZDV+3TC+NVP 300+150+200mg tabs
d4T+3TC+NVP 30+150+200mg tabs
USD Millions
ANTIRETROVIRAL MEDICINESTOP 10 FORMULATIONS 2010 YTD
0 10 20 30 40 50 60
SOUTH AFRICA
KENYA
UGANDA
INDONESIA
NIGERIA
DEM.REP.OF CONGO
BRAZIL
ZIMBABWE
ETHIOPIA
MALAWI
USD Millions
2008 2009 2010
ANTIRETROVIRAL MEDICINESTOP 10 RECEIVING COUNTRIES 2008-2010YTD
0
10
20
30
40
50
60
70
80
90
2008 2009 2010
USD
Mill
ion
s
Other
UNICEF
ESP Zimbabwe
MOH Brazil
UNITAID
PEPFAR
Global Fund
ANTIRETROVIRAL MEDICINESFUNDING SOURCES 2008-2010YTD
PROCUREMENT OF ARVs 2010UNDP PARTNERSHIP (GFATM)
Recipient USD value
UNDP - Zimbabwe 7,600,000
UNDP - DR Congo 2,895,421
UNDP - Belarus 1,143,331
UNDP - El Salvador 855,232
UNDP - Gabon 554,219
UNDP - North Sudan 410,564
UNDP - Cuba 300,370
UNDP - Uzbekistan 299,118
UNDP - Nepal 240,585
UNDP - Eq. Guinea 132,726
UNDP - Yemen 117,425
UNDP - Angola 100,240
UNDP - Tajikistan 80,085
UNDP - Iran 61,017
UNDP- South Sudan 31,960
UNDP - São Tomé 11,251
UNDP - OPT 2,003
• ANNUAL REQUEST FOR PROPOSALS EXERCISE (planned for Q4 2010)
• ALL MEDICINES IN WHO GUIDELINES
• VOLUMES: HISTORICAL OFFTAKE
• MULTIPLE TIME BOUND (12 month) LTAs
• LTA AWARDS BASED ON: TECHNICAL EVALUATION: ACCEPTABLE / NOT ACCEPTABLE
COMMERCIAL CRITERIA:
PRICE
LEAD TIMES
PRODUCT RANGE – CONSOLIDATION
PAST PERFORMANCE
• AD-HOC TENDERS FOR NON-STANDARD PRODUCTS
ANTIRETROVIRAL MEDICINESPROCUREMENT STRATEGY
• ALLOCATION OF ORDERS AMONGST LTA HOLDERS
• SECONDARY COMPETITION:
REGISTRATION
PRICE
LEAD TIMES
PRODUCT RANGE – CONSOLIDATION
DELIVERY PERFORMANCE
• DIRECT SHIPMENT BY NOMINATED FORWARDER
• EMERGENCY STOCKPILE IN COPENHAGEN WH
ANTIRETROVIRAL MEDICINESPROCUREMENT STRATEGY
ANTIRETROVIRAL MEDICINESUNICEF SUPPLIER BASE 2004-2009
0
2
4
6
8
10
12
14
16
0
50
100
150
200
250
RFP 2004 RFP 2006 RFP 2007 RFP 2008 RFP 2009
LTA
HO
LDER
S
AC
CEP
TAB
LE P
RO
DU
CTS
Approved products LTA holders
ANTIRETROVIRAL MEDICINESPMTCT - FIT FOR PURPOSE
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2009 2008 2009
Nevirapine 200mg tabs ZDV+3TC 300mg+150mg tabs
HDPE packs
Blister packs
ACTs 2007-2010YTDVALUES AND RECEIVING COUNTRIES
0
5
10
15
20
25
30
35
40
0
5
10
15
20
25
30
35
40
2007 2008 2009 2010
Co
un
trie
s
USD
Mill
ion
s
USD value Countries
0
5
10
15
20
25
30
35
40
2008 2009 2010
USD
Mill
ion
s
Others
UNICEF
UNITAID
Global Fund
UNICEF ACTsFUNDING SOURCES 2008-2010YTD
0 5 10 15 20 25 30
SIERRA LEONE
LIBERIA
GHANA
NIGER
BURUNDI
SUDAN
MALAWI
MOZAMBIQUE
ZAMBIA
ETHIOPIA
Million treatments
2008 2009 2010
ACTs 2008-2010YTDTOP 10 RECEIVING COUNTRIES
ACTsUNICEF PROCUREMENT 2010
0 5 10 15 20 25 30
Injectables
Suppositories
AS+MQ
AS+AQ co-blister
AS+SP
AS+AQ co-formulated
Artemether+lumefantrine
Million Treatments
• ANNUAL REQUEST FOR PROPOSALS EXERCISE:
JOINT WHO - UNICEF PROCESS (on going)
VOLUMES: HISTORICAL + FORECAST WHEN POSSIBLE
MULTIPLE TIME BOUND LTAs
AWARDS BASED ON:
JOINT TECHNICAL EVALUATION
COMMERCIAL CRITERIA
• AD-HOC TENDERS FOR NON-STANDARD PRODUCTS
• ALLOCATION OF ORDERS: SECONDARY COMPETITION
• SCREENING OF INCOMING ORDERS
• QUARTERLY SHARING OF FORECAST
ACTs
PROCUREMENT STRATEGY
NON-ACT ANTIMALARIALSUNICEF PROCUREMENT 2008-2010
0 500,000 1,000,000 1,500,000 2,000,000 2,500,000
Quinine inj 300mg/ml,1ml
Quinine 125mg/ml,injection, 2ml
Quinine-resorcine 100mg/ml, 4ml
Quinine 125mg/ml,injection, 4ml
Primaquine 7.5mg tabs
Chloroquine syrup 50mg/5ml
Quinine-resorcine 100mg/ml, 2ml
Quinine 500mg tabs
Chloroquine 150mg tabs
Quinine inj 300mg/ml 2ml
Quinine 300mg tabs
S+P 500+25mg tabs
USD value
2008 2009 2010
• INVITATION TO BID EVERY TWO YEARS
(planned for Q4 2010)
• IN-HOUSE TECHNICAL EVALUATION - IAPQ
• STANDARD COMMERCIAL CRITERIA
• TIME BOUND LTAs - MAIN AND BACK-UP
• SUPPLY MAINLY VIA COPENHAGEN WH
• SCREENING OF REQUEST AGAINST WHO GUIDELINES
NON-ACT ANTIMALARIALS
PROCUREMENT STRATEGY
• DEADLINE AND MODE OF SUBMISSION
• NO PROPOSAL
• COMPLETENESS OF PROPOSALS:
– TECHNICAL DOCUMENTATION & SAMPLES
– PRODUCTS AVAILABLE BUT NOT OFFERED
– PRODUCTS OFFERED BUT NOT AVAILABLE
– LICENSE RESTRICTIONS
– USE OF SUBSIDIARIES/DISTRIBUTORS
– REGULATORY INFORMATION
– SUBMISSION OF DOSSIER TO PQ
• DISCREPANCIES BETWEEN OFFERED PRODUCT AND
APPROVED DOSSIER
• BLISTER DESIGN, PACKAGING, INSERTS, ETC
• PACKAGING, PALLETIZATION, BAR CODING
• PRICE VALIDITY & LTA AMENDMENTS
• RELIABILITY OF LEAD TIMES
TENDER PROCESS: CHALLENGES
• INCOMPLETE DOCUMENTATION AT DELIVERY
• SPECIAL INSTRUCTIONS: SHIPPING MARKS, SPECIAL
PACKAGING, ETC.
• COLLABORATION WITH NOMINATED FORWARDER
• NOTIFY UNICEF OF GOODS READINESS
• INCOMPLETE DOCUMENTATION FOR PAYMENT
• REGISTRATION
• SHELF LIFE
• COLLABORATION FOR PRE-DELIVERY INSPECTION
• PRODUCTION DELAYS: ADVANCE COMMUNICATION
• DELIVERY PERFORMANCE
PURCHASE ORDERS: CHALLENGES
LTA MANAGEMENTDELIVERY PERFORMANCE MONITORING
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
2008-Q3 2008-Q4 2009-Q1 2009-Q2 2009-Q3 2009-Q4
On time delivery rate Share
THANK YOU!
ANTIRETROVIRAL MEDICINESTYPE OF TREATMENT 2010
ADULT 1st line ADULT Unspecified ADULT 2nd line
PAEDIATRIC 1st line PAEDIATRIC Unspecified PAEDIATRIC 2nd line
USD VALUE
top related